pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Vicalex
drug · antibody
save

siplizumab

Phase 2updated 3mo ago
by ITB-Med AB🔗 ChEMBL
Phase 2
community read0 votes

🐶 often sniffed alongside

top 4
  • drugImmunology1 co-mentions · 1 sources
  • companyNefro Avillion Clinical Development LLC1 co-mentions · 1 sources
  • tagImmunology1 co-mentions · 1 sources
  • tagNephrology1 co-mentions · 1 sources

Antibody drug with a maximum clinical stage of Phase 2 (across all indications), with 11 investigational indications.

targets

T-cell surface antigen CD2

all catalysts(1)

phase 2 initiation · 1
Apr 29, 2026
phase 2 initiation
4mo ago
Nefro Avillion Clinical Development LLC — siplizumab (Phase II Trial Initiation)
siplizumab
→

Trials studying siplizumab

  • phase2A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplantrecruitingn=120
  • phase2Siplizumab for Sickle Cell Disease Transplantterminatedn=1
  • phase2Delayed Tolerance Through Mixed Chimerismactive not recruitingn=20
  • phase1A Study of SIPLIZUMAB in AILD and LT Patientsrecruitingn=8
  • EP1Tolerance Through Mixed Chimerism (Sip-Tego)recruitingn=12
  • EP1An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.recruitingn=12

News(0)

no news has mentioned this drug yet

brand
Vicalex
generic
siplizumab
MOA
T-cell surface antigen CD2 inhibitor
indication
Transplant Rejection
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 8m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?